Abstract
This article discusses case reports of treatment with paliperidone palmitate in comparison with data from recent publications. Second-generation long-acting injectable antipsychotics have been shown to provide better control of psychiatric manifestations, reduce the severity of negative symptoms, improve social functioning and quality of life of patients and relatives, and reduce the burden of disease for both the healthcare system and the caregivers. The case reports presented in this article demonstrate better quality of remission in schizophrenia patients treated with one- monthly and three-monthly paliperidone palmitate formulations, due to higher effi in preventing relapses, better safety and good tolerability regardless of patient age.
Highlights
Recovery and satisfactory quality of life are the criteria for the effectiveness of modern therapy for schizophrenia
Compared to two-week long-acting injectable antipsychotics, patients treated with PP1M and PP3M had a reduction in the number of rehospitalizations and concomitant medications.[10]
We present several cases of the use of secondgeneration long-acting injectable antipsychotics to illustrate our own experience of PP1M and PP3M use
Summary
Recovery and satisfactory quality of life are the criteria for the effectiveness of modern therapy for schizophrenia. Compared to two-week long-acting injectable antipsychotics, patients treated with PP1M and PP3M had a reduction in the number of rehospitalizations and concomitant medications.[10] This is consistent with information from domestic clinical practice showing improvements in extrapyramidal symptoms following transition to paliperidone palmitate therapy and the absence of the need for correctors. In November 2018, she again cancelled maintenance therapy and was admitted to a psychiatric hospital with hallucinatory-delusional symptoms, where she was treated for three weeks She was discharged with a recommendation to continue treatment with risperidone at a dose of 2 mg before bed, followed by transfer to intramuscular administration of the long-acting suspension of risperidone at a dose of 37.5 mg once every two weeks. Her mental state can be described as a sustained medically induced remission for more than a year
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
